INOZYME PHARMA INC (INZY)

Company Profile

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-07-24. The firm is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The firm is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Company Info

INOZYME PHARMA INC

321 Summer Street, Suite 400

Boston MASSACHUSETTS 02210

P: 18573304340

CEO: Axel Bolte

Employees: 59

Website: https://www.inozyme.com/